Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Smart salvage treatment for Hodgkin lymphoma

Peter W. M. Johnson

Blood (2022) 139 (25): 3563–3564.

https://doi.org/10.1182/blood.2022016274

Published: 2022

Journal Articles

Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Isla M. Johnson, Evandro D. Bezerra, Faiqa Farrukh, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Mark R. Litzow, William J Hogan, Mithun V. Shah, Mrinal M. Patnaik, Ayalew Tefferi, Naseema Gangat

Blood (2021) 138 (Supplement 1): 219.

https://doi.org/10.1182/blood-2021-149704

Published: 2021

Journal Articles

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

Steven M. Johnson, Lori Ramkissoon, James Haberberger, Naomi L Ferguson, Jonathan Galeotti, Daniel R. Richardson, Matthew C. Foster, Jeffrey Ross, Shakti H. Ramkissoon, Joshua F. Zeidner, Daniel Duncan, Nathan Montgomery

Blood (2021) 138 (Supplement 1): 3466.

https://doi.org/10.1182/blood-2021-151796

Published: 2021

Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136373

Published: 2020

Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD

Blood (2019) 134 (Supplement_1): 4079.

https://doi.org/10.1182/blood-2019-128564

Published: 2019

Journal Articles

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Daniel R. Richardson, MD MA, David M Swoboda, MD, Anastasia Ivanova, PhD, Steven M Johnson, MD, Jonathan Galeotti, MD MS, Sonia Esparza, MD, Onyee Chan, MD, Matthew C Foster, MD, Catherine C. Coombs, MD, Nathan D Montgomery, MD, David A Sallman, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 2598.

https://doi.org/10.1182/blood-2019-122929

Published: 2019

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

Optimizing therapy in advanced-stage Hodgkin lymphoma

Sean H. Lim, Peter W. M. Johnson

Blood (2018) 131 (15): 1679–1688.

https://doi.org/10.1182/blood-2017-09-772640

Published: 2018

Journal Articles

Novel Conjugates of Butyrate and δ-Aminolevulinate Increase γ-Globin Gene Expression and Fetal Hemoglobin Synthesis in Erythroid Progenitors

Aluya R. Oseghale, BSc, Marjorie M. Johnson, BS, Xingguo Zhu, PhD, Abraham Nudelman, PhD, Ada Rephaeli, PhD, Betty S. Pace, MD

Blood (2017) 130 (Supplement 1): 3511.

https://doi.org/10.1182/blood.V130.Suppl_1.3511.3511

Published: 2017

Journal Articles

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Anna H Turaj, MSc, Vikki L Field, Claude H.T. Chan, PhD, Christine A. Penfold, BSc, Jinny H. Kim, PhD, Sonya James, PhD, Kerry L Cox, Tibor Keler, PhD, Peter M Johnson, MA, MD, Aymen Al-Shamkhani, PhD, Stephen A Beers, PhD, Martin J. Glennie, PhD, Mark S Cragg, PhD, Sean H Lim, MD PhD

Blood (2016) 128 (22): 3024.

https://doi.org/10.1182/blood.V128.22.3024.3024

Published: 2016

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD

Blood (2016) 128 (22): 4203.

https://doi.org/10.1182/blood.V128.22.4203.4203

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia

Suzanne M. Johnson, Clare Dempsey, Amy Chadwick, Stephanie Harrison, Jizhong Liu, Yujun Di, Owen J. McGinn, Marco Fiorillo, Federica Sotgia, Michael P. Lisanti, Mayur Parihar, Shekhar Krishnan, Vaskar Saha

Blood (2016) 128 (3): 453–456.

https://doi.org/10.1182/blood-2015-12-688051

Published: 2016

Journal Articles

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan M. O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, David M. Johnson, Langdon L. Miller, Yeonhee Kim, Roger D. Dansey, Ronald L. Dubowy, Steven E. Coutre

Blood (2015) 126 (25): 2686–2694.

https://doi.org/10.1182/blood-2015-03-630947

Published: 2015

Includes: Supplemental data

Journal Articles

Red Cell Band 3 Content Evaluation By Eosin Maleimide (EMA) Fluorescence: Beyond Diagnosis of Dominant Hereditary Spherocytosis (HS)

Ahmar Urooj Zaidi, MD, Miguel Herrera-Martinez, BS, Gerard W. Goyette, Jr., BS, Steven Buck, MS, Manisha Gadgeel, MBBS, Arathi Mohan, Bulent Ozgonenel, MD, Michael U Callaghan, MD, Robert M. Johnson, PhD, Yaddanapudi Ravindranath, MBBS

Blood (2015) 126 (23): 3343.

https://doi.org/10.1182/blood.V126.23.3343.3343

Published: 2015

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Suzanne M. Johnson, Clare Dempsey, Amy Chadwick, Stephanie Harrison, Jizhong Liu, Yujun Di, Owen McGinn, Mayur Parihar, Federica Sotgia, Michael Lisanti, Shekhar Krishnan, Vaskar Saha, PhD FRCP, FRCPath

Blood (2015) 126 (23): 1430.

https://doi.org/10.1182/blood.V126.23.1430.1430

Published: 2015

Journal Articles

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Blood (2015) 126 (8): 950–956.

https://doi.org/10.1182/blood-2014-12-616474

Published: 2015

Includes: Supplemental data

Journal Articles

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

Matthew D. Blunt, Matthew J. Carter, Marta Larrayoz, Lindsay D. Smith, Maria Aguilar-Hernandez, Kerry L. Cox, Thomas Tipton, Mark Reynolds, Sarah Murphy, Elizabeth Lemm, Samantha Dias, Andrew Duncombe, Jonathan C. Strefford, Peter W. M. Johnson, Francesco Forconi, Freda K. Stevenson, Graham Packham, Mark S. Cragg, Andrew J. Steele

Blood (2015) 125 (26): 4032–4041.

https://doi.org/10.1182/blood-2014-11-610329

Published: 2015

Includes: Supplemental data

NARROW

Smart salvage treatment for Hodgkin lymphoma

Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents

Comprehensive Genomic Characterization of ASXL1 C.1934dupG (p.G646fs*12) Versus Other ASXL1 mutations in Myeloid Neoplasia

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

ASXL1 / SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Optimizing therapy in advanced-stage Hodgkin lymphoma

Novel Conjugates of Butyrate and δ-Aminolevulinate Increase γ-Globin Gene Expression and Fetal Hemoglobin Synthesis in Erythroid Progenitors

Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Red Cell Band 3 Content Evaluation By Eosin Maleimide (EMA) Fluorescence: Beyond Diagnosis of Dominant Hereditary Spherocytosis (HS)

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Metabolic Reprogramming of Bone Marrow Stromal Cells By Leukemic Extracellular Vesicles in Acute Lymphoblastic Leukemia (ALL)

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only